OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NAII$2.7055

Natural Alternatives International Inc

PharmaceuticalsVerified

Natural Alternatives International Inc operates with a low debt-to-equity ratio of 0.11 and a strong current ratio of 3.98, indicating robust short-term liquidity. The company's price-to-book ratio of 0.2 and price-to-tangible-book ratio of 0.2 suggest that the market values the company significantly below its book value, potentially reflecting concerns about asset quality or future earnings potential. The company's profitability metrics are weak, with a negative return on equity of -1.88% and a negative return on assets of -1.03%. These figures fall below typical industry benchmarks for pharmaceutical and personal care product companies, indicating underperformance relative to its peers. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases exposure to market-specific risks and limits growth opportunities. The company's growth trajectory is uncertain, with no significant revenue growth reported in the latest financial period. The operating cash flow of $1.22 million is modest, and the free cash flow is negative at -$754,000, suggesting that the company is not generating sufficient cash to fund operations and capital expenditures without external financing. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the negative net income of -$1.58 million and the operating loss of -$1.95 million indicate financial stress that could necessitate future equity or debt financing, potentially leading to dilution. Recent filings and transcripts do not indicate any major strategic shifts or significant events that would alter the company's current financial trajectory. The company continues to focus on its core personal care product lines and private label arrangements.

30-day price · NAII(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyNatural Alternatives International Inc
TickerNAII.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Natural Alternatives International Inc develops and markets natural personal care products, primarily through private label and co-branded arrangements with retailers and distributors.

Classification. The company is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with a confidence level of 0.92.

Natural Alternatives International Inc operates with a low debt-to-equity ratio of 0.11 and a strong current ratio of 3.98, indicating robust short-term liquidity. The company's price-to-book ratio of 0.2 and price-to-tangible-book ratio of 0.2 suggest that the market values the company significantly below its book value, potentially reflecting concerns about asset quality or future earnings potential. The company's profitability metrics are weak, with a negative return on equity of -1.88% and a negative return on assets of -1.03%. These figures fall below typical industry benchmarks for pharmaceutical and personal care product companies, indicating underperformance relative to its peers. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases exposure to market-specific risks and limits growth opportunities. The company's growth trajectory is uncertain, with no significant revenue growth reported in the latest financial period. The operating cash flow of $1.22 million is modest, and the free cash flow is negative at -$754,000, suggesting that the company is not generating sufficient cash to fund operations and capital expenditures without external financing. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the negative net income of -$1.58 million and the operating loss of -$1.95 million indicate financial stress that could necessitate future equity or debt financing, potentially leading to dilution. Recent filings and transcripts do not indicate any major strategic shifts or significant events that would alter the company's current financial trajectory. The company continues to focus on its core personal care product lines and private label arrangements.
Key takeaways
  • The company has strong liquidity but is underperforming in terms of profitability and return metrics.
  • The low price-to-book ratio suggests the market is undervaluing the company's assets.
  • Revenue concentration in a single segment and lack of geographic diversification pose growth and risk management challenges.
  • The company is not generating positive free cash flow, which could lead to future financing needs and potential dilution.
  • --
  • # RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$25.1M
Gross profit$1.9M
Operating income-$2.0M
Net income-$1.6M
R&D
SG&A
D&A
SBC
Operating cash flow$1.2M
CapEx-$2.0M
Free cash flow-$754.0k
Total assets$153.2M
Total liabilities$69.1M
Total equity$84.1M
Cash & equivalents$12.4M
Long-term debt$9.3M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$178.5M$13.7M$10.8M$10.0M
FY-3$171.0M$13.7M$10.7M-$11.6M
FY-2$154.0M$4.7M$2.5M-$6.7M
FY-1$113.8M-$8.5M-$7.2M-$5.6M
FY0$129.9M-$8.7M-$13.6M-$12.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$120.3M$80.1M$32.1M
FY-3$146.0M$88.5M$21.8M
FY-2$134.2M$88.8M$13.6M
FY-1$162.3M$82.6M$12.0M
FY0$151.9M$68.4M$12.3M
PeriodOCFCapExFCFSBC
FY-4$20.8M-$5.1M$10.0M
FY-3$11.9M-$26.5M-$11.6M
FY-2$7.0M-$13.5M-$6.7M
FY-1-$1.5M-$3.0M-$5.6M
FY0$5.9M-$3.6M-$12.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$25.1M-$2.0M-$1.6M-$754.0k
FQ-6$29.5M-$2.5M-$1.9M-$1.7M
FQ-5$33.1M-$1.8M-$2.0M-$1.2M
FQ-4$34.1M-$2.8M-$2.2M-$2.1M
FQ-3$28.8M-$2.1M-$2.2M-$1.8M
FQ-2$33.9M-$1.9M-$7.2M-$7.5M
FQ-1$37.7M$284.0k-$291.0k-$121.0k
FQ0$34.8M-$1.8M-$2.6M-$2.3M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$153.2M$84.1M$12.4M
FQ-6$162.3M$82.6M$12.0M
FQ-5$161.3M$80.2M$10.2M
FQ-4$156.1M$79.1M$8.7M
FQ-3$154.9M$76.6M$10.6M
FQ-2$151.9M$68.4M$12.3M
FQ-1$156.9M$69.0M$7.7M
FQ0$153.3M$67.0M$3.8M
PeriodOCFCapExFCFSBC
FQ-7$1.2M-$2.0M-$754.0k
FQ-6-$1.5M-$3.0M-$1.7M
FQ-5-$3.4M-$301.0k-$1.2M
FQ-4-$3.4M-$1.4M-$2.1M
FQ-3$2.6M-$2.2M-$1.8M
FQ-2$5.9M-$3.6M-$7.5M
FQ-1-$4.0M-$1.0M-$121.0k
FQ0-$10.4M-$2.0M-$2.3M
Valuation
Market price$2.70
Market cap$16.7M
Enterprise value$13.6M
P/E
Reported non-GAAP P/E
EV/Revenue0.5
EV/Op income
EV/OCF11.1
P/B0.2
P/Tangible book0.2
Tangible book$84.1M
Net cash$3.1M
Current ratio4.0
Debt/Equity0.1
ROA-1.0%
ROE-1.9%
Cash conversion-77.0%
CapEx/Revenue-7.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricNAIIActivity
Op margin-7.8%7.7% medp25 -2.4% · p75 15.5%bottom quartile
Net margin-6.3%5.9% medp25 -3.8% · p75 12.8%bottom quartile
Gross margin7.6%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.9%-7.0% medp25 -14.9% · p75 -3.2%below median
Debt / equity11.0%25.0% medp25 3.8% · p75 63.3%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 14:17 UTC#bace062b
Market quoteclose USD 2.72 · shares 0.01B diluted
no public URL
2026-05-16 14:17 UTC#6242772c
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 16:51 UTCJob: f5faca2f